Sectors
Foley & Lardner LLP served as intellectual property counsel to Carna Health, an AI-enabled digital health company revolutionizing chronic disease prevention, in its partnership with Renalytix PLC (LSE: RENX) (OTCQB: RNLXY) to advance a novel, integrated approach to chronic kidney disease (CKD) management.
The collaboration combines Renalytix’s FDA-approved kidneyintelX.dkd™ test with Carna Health’s AI-enabled digital health platform to enable earlier identification of at-risk patients and more precise, risk-guided interventions. The integrated model is designed to help health systems shift from reactive treatment to proactive care, improving outcomes and reducing costs associated with late-stage kidney disease while supporting population-scale screening and personalized care pathways for patients with CKD and related cardio-kidney-metabolic (CKM) conditions.
Carna Health is a global AI-enabled digital health company addressing the silent, costly progression of CKM disease through population-scale screening and monitoring, predictive analytics, and care enablement. The intelligent platform aggregates point-of care and laboratory diagnostics and clinical data into a secure Patient 360, applying machine learning to identify undiagnosed risk, predict disease progression, and deliver actionable guidance to providers and patients, particularly in environments with limited specialist access.
Foley’s intellectual property team was led by partner Christopher McKenna and Aaron Maguregui.
